An AACR Special Conference in Cancer Research

Pancreatic Cancer

September 29-30, 2021 | Virtual Special Conference

Conference Cochairs:

Andrew M. Lowy, UC San Diego, La Jolla, CA
Marina Pasca di Magliano, University of Michigan Medical School, Ann Arbor, MI
Robert H. Vonderheide, Penn Medicine Abramson Cancer Center, Philadelphia, PA
Jen Jen Yeh, University of North Carolina, Chapel Hill, NC

All times listed are in Eastern Time, US

WEDNESDAY, SEPTEMBER 29

10:00 a.m.-10:45 a.m. Opening Session

10:00 a.m.-10:05 a.m. **Welcome from Cochairs**
Marina Pasca di Magliano, University of Michigan Medical School, Ann Arbor, MI

10:05 a.m.-10:10 a.m. **Welcome from Lead Supporters**
Linda Tantawi, Lustgarten Foundation, Woodbury, NY

10:10 a.m.-10:45a.m **Rising Star Keynote**
Molecular subtypes and vulnerabilities in pancreatic cancer
Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, MA

10:45 a.m.-11:00 a.m. BREAK

11:00 a.m.-12:45 p.m. Session 1-Immunotherapy Translation in Progress
Moderator: Robert H. Vonderheide, Penn Medicine Abramson Cancer Center, Philadelphia, PA

11:00 a.m.-11:25 a.m. Session Keynote:
Dendritic cell corner stone of tumor immunity in PDAC
David G. DeNardo, Washington University School of Medicine, St. Louis, MO

11:25 a.m.-11:40 a.m. ***Ex vivo* co-culture system with patient-derived organoids to assess CXCR4 inhibitor as an immune modulating agent for human pancreas adenocarcinoma**
Emily Alouani*, Columbia University, New York, NY

11:40 a.m.-11:55 a.m. **A phase II pilot trial of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + cisplatin (C) + gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC)**
Erkut H. Borazanci*, HonorHealth/TGen, Scottsdale, AZ

11:55 a.m.-12:10 p.m. **High quality neoantigens are immunoedited in long-term pancreatic cancer survivors**
Luis A. Rojas*, Memorial Sloan Kettering Cancer Center, New York, NY

12:10 p.m.-12:25 p.m. **Inhibition of focal adhesion kinase (FAK) improves pancreatic ductal adenocarcinoma's response to immunotherapy by targeting cancer stem cells (CSCs)**
Yezi Zhu*, Livestrong Cancer Institute, Austin, TX

12:25 p.m.-12:30 p.m. Discussant: Reginald Hill, Ellison Institute for Transformative Medicine of USC, Los Angeles, CA

12:30 p.m.-12:45 p.m. Discussion

12:45 p.m.-1:15 p.m. BREAK

1:15 p.m.-2:00 p.m. Career Breakout Rooms

- Transitioning from Academics to Industry
  - David J. Shields, Pfizer, New York, NY
  - Christina Twyman-Saint Victor, Bristol-Myers Squibb, Piscataway, NJ
- Collaborating with Industry
  - Jane Grogan, Graphite Bio, South San Francisco, CA
  - Channing Der, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
- Starting Your Lab
  - Yuliya Pylayeva-Gupta, University of North Carolina at Chapel Hill
  - Christopher J. Halbrook, University of California Irvine, Irvine, CA
- Getting Tenure
  - Zobeida Cruz-Monserrate, The Ohio State University Wexner Medical Center, Columbus, OH
  - Rushika M. Perera, University of California San Francisco, San Francisco, CA
- Balancing Clinical and Research Life
  - Susan Tsai, Medical College of Wisconsin, Wauwatosa, WI
  - Jen Jen Yeh, University of North Carolina, Chapel Hill, NC
- Mentoring the Mentor
  - Lisa M. Coussens, OHSU Knight Cancer Center, Portland, OR
  - Howard C. Crawford, Henry Ford Pancreatic Cancer Center, Detroit, MI

2:00 p.m.-2:30 p.m. BREAK

2:30 p.m.-4:00 p.m. Session 2-Big Data
Moderator: Jen Jen Yeh, University of North Carolina, Chapel Hill, NC

2:30 p.m.-3:00 p.m. Session Keynote
Proteogenomic characterization of pancreatic ductal adenocarcinoma
Hui Zhang, Johns Hopkins University, Baltimore, MD

3:00 p.m.-3:15 p.m. **Chromatin dynamics *in vivo* define coordinate functions of inflammation and mutant Kras in pancreatic tumorigenesis**
Rohit Chandwani*, Weill Cornell Medicine, New York, NY

3:15 p.m.-3:30 p.m. **Integrative genomic characterization of therapeutic targets for pancreatic cancer**
Jimmy A. Guo*, Broad Institute of MIT and Harvard, Cambridge, MA

3:30 p.m.-3:45 p.m. **Lung-tropic, liver-averse, primary PDAC tumors are associated with greater peripheral T cell diversity and have a unique, subtype-independent, gene-expression signature that significantly correlates with longer survival**
Jason M. Link*, Oregon Health & Science University, Portland, OR

3:45 p.m.-3:50 p.m. Discussant 2: Eric A. Collisson, University of California San Francisco, San Francisco, CA

3:50 p.m.-4:00 p.m. Discussion

THURSDAY, SEPTEMBER 30

10:00 a.m.-10:45 a.m. Keynote Lecture
Moderator: Jen Jen Yeh, University of North Carolina, Chapel Hill, NC

Using an integrative molecular epidemiology approach to battle pancreatic cancer in the era of precision medicine: Hope is on the horizon
Jennifer B. Permuth, H. Lee Moffitt Cancer Center, Tampa, FL

10:45 a.m.-11:00 a.m. BREAK

11:00 a.m.-12:45 p.m. Session 3-Metabolism and Ras Signaling
Moderator: Andrew M. Lowy, UC San Diego, La Jolla, CA

11:00 a.m.-11:25 a.m. Session Keynote:
Metabolic stress in pancreatic cancer progression and therapy
Cosimo Commisso, Sanford Burnham Prebys Medical Discovery Institute, San Diego, CA

11:25 a.m.-11:40 a.m. **Kdm6 demethylases are critical regulators of pancreatic cancer initiation, progression and subtype specification**
Laura Leonhardt*, University of California San Francisco, San Francisco, CA

11:40 a.m.-11:55 a.m. **Targeting the sterol regulatory element-binding protein pathway in pancreatic ductal adenocarcinoma**
Stephanie Myers*, Johns Hopkins University, Baltimore, MD

11:55 a.m.-12:10 p.m. **Collateral amplification of the *KRAS* linked gene *PTHLH* governs pancreatic cancer growth and metastasis and reveals a new therapeutic vulnerability**
Jason R. Pitarresi*, University of Pennsylvania, Philadelphia, PA

12:10 p.m.-12:25 p.m. **Loss of compensatory feedback mechanism involving splicing factor SRSF1 accelerates *Kras*^{G12D}-mediated pancreatic cancer initiation**
Ledong Wan*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

12:25 p.m.-12:30 p.m. Discussant- Donita Brady, Perelman School of Med. Univ. of Pennsylvania

12:30 p.m.-12:45 p.m. Discussion

12:45 p.m.-1:15 p.m. BREAK

1:15 p.m.-3:05 p.m. Session 4-Tumor Microenvironment
Moderator: Marina Pasca Di Magliano, University of Michigan Medical School, Ann Arbor, MI

1:15 p.m.-1:40 p.m. Session Keynote
Rebalancing dysregulated tumor microenvironments in pancreatic cancer progression
Rosandra N. Kaplan, National Cancer Institute, Bethesda, MD

1:40 p.m.-1:55 p.m. **The splanchnic mesenchyme during fetal development is the major source of pancreatic cancer associated fibroblasts**
Lu Han*, Medical University of South Carolina, Charleston, SC

1:55 p.m.-2:10 p.m. **Hedgehog represses angiogenesis in PDAC through a paracrine cascade mediated by Wif1**
Marie C. Hasselluhn*, Columbia University, New York, NY

2:10 p.m.-2:25 p.m. **Cancer-associated fibroblasts sustain critical dependency of pancreatic cancer cells on exogenous lipids**
Charline Ogier*, Fox Chase Cancer Center, Philadelphia, PA

2:25 p.m.-2:40 p.m. **Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming**
Ashley Velez-Delgado*, University of Michigan, Ann Arbor, MI

2:40 p.m.-2:45 p.m. Discussant: Mara H. Sherman, OHSU Knight Cancer Center, Portland, OR

2:45 p.m.-3:05 p.m. Discussion

3:05 p.m.-3:30 p.m. BREAK

3:30 p.m.-4:30 p.m. Debate: The KPC model has helped advance pancreatic cancer therapy: Agree or disagree?

Moderator: Anirban Maitra, UT MD Anderson Cancer Center, Houston, TX

3:30 p.m.-3:50 p.m. Kenneth P. Olive, Herbert Irving Comprehensive Cancer Center, New York, NY

3:50 p.m.-4:10 p.m. Phoebe Phillips, University of New South Wales, Sydney, Australia

4:10 p.m.-4:30 p.m. Discussion

4:30 p.m.- 4:35 p.m. Closing Statements

Andrew M. Lowy, UC San Diego, La Jolla, CA